KEYNOTE-B61: Lenvatinib Plus Pembrolizumab in Non–Clear Cell RCC
Focusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma.
Read More
TKI Monotherapy Data in Non–Clear Cell RCC
Chandler H. Park, MD, highlights cabozantinib monotherapy data from the SWOG 1500 study in non–clear cell renal cell carcinoma.
Read More
Overview of Non–Clear Cell RCC
The expert panel gives an overview of non–clear cell renal cell carcinoma, highlighting disease subtypes and treatment approaches.
Read More
Clinical Insights on Belzutifan in Advanced RCC
Following a review of research on belzutifan in the advanced RCC space, the expert panel has a comprehensive discussion on treatment approaches and toxicity management.
Read More
Updates on LITESPARK-005 and LITESPARK-011 in Advanced RCC
Focusing on belzutifan, Laurence Albigès, MD, PhD, reviews data from the LITESPARK-005 clinical trial, and Martin H. Voss, MD, discusses the ongoing LITESPARK-011 trial.
Read More
CONTACT-03: Atezolizumab Plus Cabozantinib in Advanced RCC
Experts on advanced RCC discuss the CONTACT-03 trial evaluating atezolizumab plus cabozantinib following immune checkpoint inhibitor treatment in patients with inoperable disease.
Read More
Treatment Decisions in the Second Line and Beyond in Advanced Clear Cell RCC
David A. Braun, MD, PhD, provides clinical insights on factors that influence treatment decisions in the second line and beyond for patients with advanced clear cell RCC.
Read More
LITESPARK-003 and LITESPARK-024: Ongoing Belzutifan Research
Focusing on the LITESPARK-003 and LITESPARK-024 trials, Laurence Albigès, MD, PhD, discusses novel doublet regimens under investigation in the first-line setting in advanced renal cell carcinoma.
Read More
Clinical Pearls for Managing IO-TKI and IO-IO Toxicity in Advanced RCC
Medical oncologists provide clinical insights on managing adverse events associated with IO-TKI and IO-IO regimens in patients with advanced renal cell carcinoma.
Read More
CheckMate 9ER: Nivolumab Plus Cabozantinib in Newly Diagnosed Advanced RCC
The expert panel reacts to 55-month follow-up data from CheckMate 9ER assessing nivolumab plus cabozantinib in patients with newly diagnosed advanced RCC.
Read More
Lenvatinib Plus Pembrolizumab Network Meta-Analysis and Outcomes with Cabozantinib in Advanced RCC
David A. Braun, MD, PhD, shares his takeaways from the network meta-analysis on lenvatinib plus pembrolizumab in advanced RCC, and Martin H. Voss, MD, discusses outcomes with cabozantinib following frontline lenvatinib plus pembrolizumab.
Read More
LEAP Study: Lenvatinib Plus Pembrolizumab in Patients With RCC and Brain Metastasis
Chandler H. Park, MD, discusses the LEAP study investigating lenvatinib plus pembrolizumab in patients with renal cell carcinoma with brain metastasis.
Read More
Recent Subgroup Analyses from the CLEAR study in Advanced RCC
Martin H. Voss, MD, gives an overview of the CLEAR study evaluating lenvatinib plus pembrolizumab in frontline advanced RCC and discusses recent subgroup analyses.
Read More
CheckMate 67T: Subcutaneous vs IV Nivolumab in Previously Treated Advanced RCC
Laurence Albigès, MD, PhD, reviews recently presented data from CheckMate 67T, which is assessing subcutaneous vs intravenous nivolumab in patients with previously treated RCC.
Read More
Long-Term Follow-Up from CheckMate 214 in Advanced RCC
The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.
Read More
First-Line Treatments for Advanced Clear Cell RCC
A panel of medical oncologists who specialize in renal cell carcinoma (RCC) introduce themselves and discuss the first-line treatment landscape and risk stratification of clear cell RCC.
Read More
Determining the Optimal Use of Adjuvant Immunotherapy in Renal Cell Carcinoma
June 19th 2023Kidney and renal pelvis cancers are one of the 10 most common new malignant diagnoses in both men and women in the United States, with an estimated 52,360 new cases in men and 29,440 new cases in women per year.
Read More